Issue 44, 2022

A focus on the discovery of potent and selective cyclic peptide scaffolds for drug development

Abstract

In the past, cyclic peptide drugs were commonly discovered by isolation of natural products. However, recent efforts predominantly use high-throughput synthetic or genetically encoded libraries to find potent and selective hits against a range of challenging therapeutic targets. Kawamura et al. (Chem. Sci., 2022, 13, 3256–3262, https://doi.org/10.1039/D1SC06844J) developed a new workflow that can be applied to mRNA display, using high-throughput clustering, SAR investigations and in silico structural studies. This led to the discovery of nanomolar, serum-stable cyclic peptides against the human glucose-dependent insulinotropic peptide receptor (hGIP-R).

Graphical abstract: A focus on the discovery of potent and selective cyclic peptide scaffolds for drug development

Article information

Article type
Commentary
First published
04 nov. 2022
This article is Open Access

All publication charges for this article have been paid for by the Royal Society of Chemistry
Creative Commons BY license

Chem. Sci., 2022,13, 12942-12944

A focus on the discovery of potent and selective cyclic peptide scaffolds for drug development

G. J. Saunders and A. K. Yudin, Chem. Sci., 2022, 13, 12942 DOI: 10.1039/D2SC90214A

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements